January 29, 2021


Servier’s American cancer experiment

January 22, 2021

The Pharma Letter

"Very, very busy" Servier Pharma enough to keep CEO up at night

January 14, 2021

Wall Street Journal

Biotech Startup Acquisitions Jumped in 2020, Leaving VCs Optimistic for New Year

January 12, 2021

Endpoints News

Once aiming to double oncology pipeline, Servier's US branch touts rapid pace in building its foothold in the space

December 21, 2020


Agios sells cancer business to French drug maker for up to $2 billion, will now focus on inherited diseases

December 21, 2020

Boston Globe

Cambridge biotech Agios to sell oncology business to Boston’s Servier for up to $2 billion

December 21, 2020

Endpoints News

Agios pivots away from oncology, auctioning off cancer pipeline for $2B and shifting the spotlight in restructuring

December 21, 2020


Agios to Sell Cancer Portfolio to Servier for $1.8 Billion

December 14, 2020

The Long Run with Luke Timmerman

Seeking Impact: Servier's David Lee on The Long Run Podcast

December 4, 2020

Yahoo Finance

Precision BioSciences Reports Positive Interim Results from PBCAR0191 Phase 1/2a Trial in Relapsed/Refractory (R/R) Non-Hodgkin Lymphoma (NHL) and R/R B-cell Acute Lymphoblastic Leukemia (B-ALL)

February 5, 2020

Business Insider

The 37-Year-Old CEO of A Major Pharma Company Lays Out the Three-Part Strategy That Drove His Career

July 25, 2019

GMP News

Servier Announced First Private Placement on the US Market

June 28, 2019


Servier Pharmaceuticals Executive Highlights Pipeline, ‘Focus on the Patients’

June 7, 2019

Fierce Pharma

Servier, Armed with Shire Cancer Drugs, Builds Out Vision for U.S. Future

May 13, 2019

Area Development

Servier Pharmaceuticals Opens U.S. Headquarters in Boston, Massachusetts

May 9, 2019

Boston Globe

French Drug Maker Servier Sets up US Headquarters in Seaport

May 9, 2019

Boston Business Journal

Servier Launches U.S. Cancer Business with Plans to Double Headcount in Next 5 Years

May 9, 2019

BioPharma Dive

Servier's US Push Takes Shape as Boston HQ Opens

December 20, 2018


FDA Approves Asparlas for Acute Lymphoblastic Leukemia

July 20, 2018

Fierce Pharma

Servier Picks Shire Executive to Run U.S. Business Being Built Out of Deal for Shire’s Oncology Unit

June 8, 2018

Endpoints News

After Snatching Up Shire's Cancer Unit, French Pharma Giant Servier to Expand US Presence with Kendall Square Innovation Office

More from Servier

Research & Development

We invest in innovative research and development through our own development or partnerships to best address the unmet needs of patients.

Learn More

Clinical Trials

We strive to have consistent and concise transparency throughout all our clinical trials and research and development for the benefit of our patients.

Learn More

About Us

Servier Pharmaceuticals is a privately held pharmaceutical company focused on Oncology. Everything we do is to bring the promise of tomorrow to the patients we serve.

Learn More